Great West Life Assurance Co. Can boosted its holdings in PRA Health Sciences Inc (NASDAQ:PRAH) by 402.2% in the second quarter, HoldingsChannel.com reports. The firm owned 29,649 shares of the medical research company’s stock after acquiring an additional 23,745 shares during the period. Great West Life Assurance Co. Can’s holdings in PRA Health Sciences were worth $2,767,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Ostrum Asset Management acquired a new position in shares of PRA Health Sciences during the first quarter valued at $108,000. Twin Tree Management LP acquired a new position in shares of PRA Health Sciences during the second quarter valued at $120,000. Fox Run Management L.L.C. acquired a new position in shares of PRA Health Sciences during the second quarter valued at $201,000. Mackay Shields LLC acquired a new position in shares of PRA Health Sciences during the first quarter valued at $207,000. Finally, Intrust Bank NA acquired a new position in shares of PRA Health Sciences during the second quarter valued at $211,000. 98.82% of the stock is owned by hedge funds and other institutional investors.

PRAH stock opened at $111.63 on Friday. The stock has a market capitalization of $7.08 billion, a P/E ratio of 34.88, a P/E/G ratio of 1.67 and a beta of 0.51. PRA Health Sciences Inc has a fifty-two week low of $73.23 and a fifty-two week high of $112.88. The company has a debt-to-equity ratio of 1.33, a current ratio of 0.93 and a quick ratio of 0.93.

PRA Health Sciences (NASDAQ:PRAH) last posted its quarterly earnings data on Wednesday, August 1st. The medical research company reported $1.00 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.12. The business had revenue of $722.84 million during the quarter, compared to the consensus estimate of $706.57 million. PRA Health Sciences had a net margin of 4.25% and a return on equity of 24.52%. The company’s quarterly revenue was up 35.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.79 earnings per share. analysts anticipate that PRA Health Sciences Inc will post 3.89 EPS for the current fiscal year.

In related news, major shareholder Pra Investors L.P. Kkr sold 6,500,000 shares of the company’s stock in a transaction dated Thursday, August 9th. The shares were sold at an average price of $101.01, for a total value of $656,565,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.85% of the company’s stock.

Several equities analysts have recently issued reports on PRAH shares. KeyCorp reissued a “buy” rating and set a $115.00 price target on shares of PRA Health Sciences in a report on Thursday, August 2nd. Jefferies Financial Group reissued a “buy” rating and set a $115.00 price target on shares of PRA Health Sciences in a report on Friday, July 20th. Zacks Investment Research raised shares of PRA Health Sciences from a “hold” rating to a “buy” rating and set a $105.00 price target for the company in a report on Tuesday, July 3rd. SunTrust Banks boosted their price target on shares of PRA Health Sciences from $100.00 to $110.00 and gave the company a “buy” rating in a report on Friday, August 3rd. Finally, ValuEngine raised shares of PRA Health Sciences from a “hold” rating to a “buy” rating in a report on Tuesday, June 12th. One equities research analyst has rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $109.44.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

See Also: Discover Your Risk Tolerance

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences Inc (NASDAQ:PRAH).

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.